Login to Your Account

Analysts Less Sure

NPS Not Shaken by Gattex Phase III Safety Concerns

By Trista Morrison
Staff Writer

Tuesday, November 1, 2011

Just nine months ago, shares of NPS Pharmaceuticals Inc. jumped 32 percent on positive Phase III data for Gattex (teduglutide) in short bowel syndrome. But on Monday those gains were erased – and then some – in the wake of concerns about three cancer cases in the Phase III follow-on trial.

NPS' stock (NASDAQ:NPSP) fell $2.59, or 33.4 percent, to close Monday at $5.17.

The concerns stemmed from data presented at the American College of Gastroenterology annual meeting, particularly an interim analysis of the open-label, follow-on STEPS 2 trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription